Content deleted Content added
Undid revision 1226457250 by A455bcd9 (talk) Self revert: might be incorrect |
Citation bot (talk | contribs) Altered doi-broken-date. | Use this bot. Report bugs. | Suggested by Whywhenwhohow | #UCB_webform 473/962 |
||
| (One intermediate revision by one other user not shown) | |||
Line 31:
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_CA =
| legal_CA_comment = /{{nbsp}}OTC<ref>{{cite web | title=Ferinject Product information | website=[[Health Canada]] | date=11 March 2024 | url=https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103479 | access-date=21 June 2024}}</ref><ref>{{cite web | title=Health product highlights 2021: Annexes of products approved in 2021 | website=[[Health Canada]] | date=3 August 2022 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-product-highlights-2021/appendices.html | access-date=25 March 2024}}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
Line 185:
Iron carboxymaltose is marketed as Ferinject,<ref name="Ferinject SmPC" /> Injectafer,<ref name="Injectafer FDA label" /><ref>{{cite web | title=Drug Approval Package: Injectafer (ferric carboxymaltose) Injection NDA #203565 | website=U.S. [[Food and Drug Administration]] (FDA) | date=4 September 2013 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203565Orig1s000TOC.cfm | access-date=8 February 2024}}</ref> and Iroprem in various countries.<ref name="CançadoMuñoz2011"/> The most common side effects are [[headaches]] which occur in 3.3%, and hypophosphatemia, which occurs in more than 35%.<ref name="Ferinject SmPC" /><ref name="Injectafer FDA label">{{cite web | title=Injectafer- ferric carboxymaltose injection injection, solution; Injectafer- ferric carboxymaltose injection, solution | website=DailyMed | date=1 May 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de | access-date=8 February 2024}}</ref>
Iron isomaltoside 1000 (brand name Monofer) is a formulation of parenteral iron that has a matrix structure that results in very low levels of free iron and labile iron. It can be given at high doses – 20 mg/kg in a single visit – no upper dose limit. This formulation has the benefit of giving a full iron correction in a single visit.<ref>{{cite journal | vauthors = Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, Hofmeister W, Muñoz M, Bock K, Meldal M, Langguth P | title = A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications | journal = European Journal of Pharmaceutics and Biopharmaceutics | volume = 78 | issue = 3 | pages = 480–491 | date = August 2011 | pmid = 21439379 | doi = 10.1016/j.ejpb.2011.03.016 }}</ref><ref name="CançadoMuñoz2011">{{cite journal | vauthors = Cançado RD, Muñoz M | title = Intravenous iron therapy: how far have we come? | journal = Revista Brasileira de Hematologia e Hemoterapia | volume = 33 | issue = 6 | pages = 461–469 | year = 2011 | pmid = 23049364 | pmc = 3459360 | doi = 10.5581/1516-8484.20110123 | doi-broken-date =
[[Ferric maltol]], marketed as Accrufer<ref name="Drug Approval Package: Accrufer">{{cite web | title=Drug Approval Package: Accrufer | website=U.S. [[Food and Drug Administration]] (FDA) | date=14 August 2019 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212320Orig1s000TOC.cfm | access-date=8 February 2024}}</ref> and Ferracru, is available in oral and intravenous preparations. When used as a treatment for IBD-related anemia, very low certainty evidence suggests a marked benefit with oral ferric maltol compared with placebo. However it was unclear whether the IV preparation was more effective than oral ferric maltol.<ref name=":0" />
| |||